These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14724989)

  • 1. [Heart failure. Can vasopressin antagonists improve the prognosis?].
    MMW Fortschr Med; 2003 Nov; 145(48):10. PubMed ID: 14724989
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of tolvaptan in acute decompensated heart failure.
    Ho JE; Teerlink JR
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):601-8. PubMed ID: 18510477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin antagonism: a future treatment option in heart failure.
    Sanghi P; Uretsky BF; Schwarz ER
    Eur Heart J; 2005 Mar; 26(6):538-43. PubMed ID: 15695526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyponatremia and outcomes in patients with heart failure.
    Goldsmith SR
    Heart; 2012 Dec; 98(24):1761-2. PubMed ID: 23204533
    [No Abstract]   [Full Text] [Related]  

  • 5. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
    Schwarz ER; Sanghi P
    Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
    Ghali JK; Tam SW
    J Card Fail; 2010 May; 16(5):419-31. PubMed ID: 20447579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
    Greenberg A
    Am J Kidney Dis; 2007 Dec; 50(6):904-7. PubMed ID: 18037090
    [No Abstract]   [Full Text] [Related]  

  • 8. Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy?
    Filippatos G; Parissis JT
    J Card Fail; 2008 Oct; 14(8):648-50. PubMed ID: 18926435
    [No Abstract]   [Full Text] [Related]  

  • 9. [Disorders of body water regulation and the therapy--vasopressin antagonists].
    Ishikawa S; Saito T
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1654-9. PubMed ID: 9410978
    [No Abstract]   [Full Text] [Related]  

  • 10. [Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].
    Yamamura Y; Sato O; Fujiki H
    Nihon Rinsho; 2007 May; 65 Suppl 5():164-8. PubMed ID: 17571379
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolvaptan (Otsuka).
    Doggrell SA
    Curr Opin Investig Drugs; 2004 Sep; 5(9):977-83. PubMed ID: 15503654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyponatraemia, antagonists of the antidiuretic hormone and cardiac failure].
    de Groote P
    Arch Mal Coeur Vaiss; 2006 Mar; 99(3):215-20. PubMed ID: 16618024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new class of heart failure drugs? Tolvaptan could be a welcome helper for "water pills" and their potentially serious side effects.
    Health News; 2004 Sep; 10(9):13. PubMed ID: 15597452
    [No Abstract]   [Full Text] [Related]  

  • 14. Conivaptan: promise of treatment in heart failure.
    Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
    Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial.
    Pitt B; Gheorghiade M
    Eur J Heart Fail; 2011 Dec; 13(12):1261-3. PubMed ID: 22102625
    [No Abstract]   [Full Text] [Related]  

  • 16. New heart failure drug shows promise.
    Health News; 2004 Jun; 10(6):14. PubMed ID: 15199906
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
    Pang PS; Gheorghiade M; Dihu J; Swedberg K; Khan S; Maggioni AP; Grinfeld L; Zannad F; Burnett JC; Ouyang J; Udelson JE; Konstam MA
    Am Heart J; 2011 Jun; 161(6):1067-72. PubMed ID: 21641352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conivaptan Yamanouchi.
    Doggrell SA
    Curr Opin Investig Drugs; 2005 Mar; 6(3):317-26. PubMed ID: 15816509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.
    Gheorghiade M; Gattis WA; Barbagelata A; Adams KF; Elkayam U; Orlandi C; O'Connor CM;
    Am Heart J; 2003 Feb; 145(2 Suppl):S51-4. PubMed ID: 12594452
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging diuretics for the treatment of heart failure.
    Sedghi Y; Gaddam KK; Ventura HO
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):195-204. PubMed ID: 19196235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.